Original Article

You have full text access to this OnlineOpen article

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

  1. Joseph M. Unger M.S.1,†,*,
  2. Ian M. Thompson Jr. M.D.2,
  3. Michael LeBlanc Ph.D.1,
  4. John J. Crowley Ph.D.1,
  5. Phyllis J. Goodman M.S.1,
  6. Leslie G. Ford M.D.3,
  7. Charles A. Coltman Jr. M.D.4

Article first published online: 28 FEB 2005

DOI: 10.1002/cncr.20919

Issue

Cancer

Cancer

Volume 103, Issue 7, pages 1375–1380, 1 April 2005

Additional Information

How to Cite

Unger, J. M., Thompson, I. M., LeBlanc, M., Crowley, J. J., Goodman, P. J., Ford, L. G. and Coltman, C. A. (2005), Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer, 103: 1375–1380. doi: 10.1002/cncr.20919

Author Information

  1. 1

    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington

  2. 2

    University of Texas Health Science Center, San Antonio, San Antonio, Texas

  3. 3

    National Cancer Institute, Bethesda, Maryland

  4. 4

    Southwest Oncology Group Operations Office, San Antonio, Texas

  1. †

    Fax: (210) 677-0006

*Southwest Oncology Group (SWOG-9217), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217

Publication History

  1. Issue published online: 18 MAR 2005
  2. Article first published online: 28 FEB 2005
  3. Manuscript Accepted: 3 DEC 2004
  4. Manuscript Revised: 22 NOV 2004
  5. Manuscript Received: 5 AUG 2004

Funded by

  • National Cancer Institute, Department of Health and Human Services. Grant Numbers: CA37429, CA38926, CA32102

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (151K)

REFERENCES

  • 1
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215–224.
  • 2
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998; 90: 1371–1388.
  • 3
    Scardino PT. The prevention of prostate cancer—the dilemma continues. N Engl J Med. 2003; 349: 297–299.
  • 4
    Pitts WR. Finasteride and promotion of high-grade prostate cancer. Oncol Times. 2003; 25: 4–5.
  • 5
    Unger JM, LeBlanc M, Crowley JJ, et al. Estimating the impact of new, clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial Lecture. J Clin Oncol. 2003; 21(23 Suppl ): 246–252.
  • 6
    Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol. 2004; 22: 362–368.
  • 7
    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973–1998) [released April, 2001, based on the August, 2000 submission]. Bethesda: National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, 2001.
  • 8
    National Center for Health Statistics. Vital statistics of the United States, 1992, vol II, section 6 life tables. Washington, DC: Public Health Service, 1996.
  • 9
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975–980.
  • 10
    Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 1995; 16: 150–163.
  • 11
    Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology. 1997; 49(3A Suppl ): 16–22.
  • 12
    Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996; 14(2 Suppl ): 22–31.
  • 13
    Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996; 78: 376–381.
    Direct Link:
View Full Article (HTML) Get PDF (151K)